Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gabapentin + venlafaxine
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gabapentin + venlafaxine is a combination of two pharmaceutical drugs, gabapentin and venlafaxine, used primarily in the management of neuropathic pain and certain psychiatric or somatic symptom disorders. Gabapentin is an anticonvulsant that modulates voltage-gated calcium channels to reduce excitatory neurotransmitter release, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake at presynaptic terminals. This combination has been studied for enhanced efficacy in patients with neuropathic pain who do not respond adequately to monotherapy with either agent. Some studies report improved pain control, mood disturbance, and quality of life when both drugs are used together; however, there may be negative pharmacodynamic interactions under certain conditions[1][3][4].
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on gabapentin + venlafaxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gabapentin + venlafaxine.